Search results for "thrombocytopenia"

showing 6 items of 76 documents

Platelet Phenotyping and Function Testing in Thrombocytopenia.

2021

Patients who suffer from inherited or acquired thrombocytopenia can be also affected by platelet function defects, which potentially increase the risk of severe and life-threatening bleeding complications. A plethora of tests and assays for platelet phenotyping and function analysis are available, which are, in part, feasible in clinical practice due to adequate point-of-care qualities. However, most of them are time-consuming, require experienced and skilled personnel for platelet handling and processing, and are therefore well-established only in specialized laboratories. This review summarizes major indications, methods/assays for platelet phenotyping, and in vitro function testing in bl…

medicine.medical_specialtyPlatelet disorderlcsh:MedicinethrombocytopeniaReview030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineplatelet function testsmedicineplatelet disordersPlateletAcquired thrombocytopeniaIntensive care medicineReduced platelet countbusiness.industryflow cytometrylcsh:RGeneral Medicineplatelet countbleedingClinical PracticeFunction analysisPlatelet function testbusiness030215 immunologyJournal of clinical medicine
researchProduct

Subarachnoid Hemorrhage Revealing Moyamoya Syndrome in a Patient With May-Hegglin Anomaly.

2017

Etude de cas; Introduction: Moyamoya syndrome is a rare progressive cerebrovascular occlusive disease for which several associated conditions have been described. Case Report: We report the case of a 76-year-old woman with a history of May-Hegglin anomaly who presented with an isolated unusual diffuse headache. Initial laboratory investigations showed only thrombocytopenia (platelet count 95000/mu L). Unenhanced brain computed tomography scan revealed a small subarachnoid hemorrhage in the left frontal lobe. Computed tomography angiography showed occlusion of the terminal portion of the left internal carotid artery (ICA) and narrowing of the terminal portion of the right ICA with abnormal c…

medicine.medical_specialtySubarachnoid hemorrhageMay-Hegglin anomalyHearing Loss SensorineuralOcclusive diseaseLeft frontal lobe030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineAneurysm[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemOcclusionmedicineHumansComputed tomography angiographyAgeddiseasemedicine.diagnostic_testbusiness.industryBrainGeneral MedicineSubarachnoid Hemorrhagemedicine.diseasestrokeThrombocytopeniaStenosismoyamoyaMay–Hegglin anomaly[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]FemaleNeurology (clinical)RadiologyMoyamoya DiseasebusinessTomography X-Ray Computed030217 neurology & neurosurgery[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe neurologist
researchProduct

Anticoagulation in a Neurosurgical Patient with Heparin-Induced Thrombocytopenia Type II with Argatroban and Fondaparinux after Clipping of an Intrac…

2009

Background: Therapeutic anticoagulation in patients after a major neurosurgical procedure remains critical because of the risk of a major intracranial bleed. Novel drugs could play

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentHematologyClipping (medicine)Case Report · Kasuistikmedicine.diseaseFondaparinuxArgatrobanNeurosurgical ProcedureSurgeryAneurysmNeurosurgical patientHeparin-induced thrombocytopeniamedicineImmunology and AllergyNeurosurgerybusinessmedicine.drug
researchProduct

Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature.

2018

Venous Thromboembolism (VTE) frequently complicates the course of hematologic malignancies (HM) and its incidence is similar to that observed in high-risk solid tumors. Despite that, pharmacologic prophylaxis and treatment of VTE in patients with HM is challenging, mainly because a severe thrombocytopenia frequently complicates the course of treatments or may be present since diagnosis, thus increasing the risk of bleeding. Therefore, in this setting, safe and effective methods of VTE prophylaxis and treatment have not been well defined and hematologists generally refer to guidelines produced for cancer patients that give indications on anticoagulation in patients with thrombocytopenia. In …

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentvenous thromboembolismLow molecular weight heparinHemorrhage030204 cardiovascular system & hematologyVte prophylaxis03 medical and health sciences0302 clinical medicineAntithromboticmedicineAnimalsHumanscardiovascular diseasesIntensive care medicineChemotherapybusiness.industryIncidence (epidemiology)IncidenceCancerAnticoagulantsHematologyVenous ThromboembolismHeparin Low-Molecular-Weightmedicine.diseaseThrombocytopeniaSevere thrombocytopeniaOncology030220 oncology & carcinogenesisHematologic NeoplasmsbusinessVenous thromboembolismCritical reviews in oncology/hematology
researchProduct

Child-Pugh Class and Not Thrombocytopenia Impacts the Risk of Complications of Endoscopic Band Ligation in Patients with Cirrhosis and High Risk Vari…

2023

Background and Aims: Endoscopic band legation (EBL) is an effective method for the prophylaxis of acute variceal bleeding (AVB). This procedure may be associated with several complications, particularly bleeding. Our analysis aimed to evaluate the risk of complications due to EBL in a cohort of patients who underwent EBL for the prophylaxis of variceal bleeding and the eventual presence of risk predictors. Patients and Methods: We retrospectively analysed data from consecutive patients who underwent EBL in a primary prophylaxis regimen. For all patients, simultaneously with EBL, we recorded the Child–Pugh and MELD score, platelet count and US features of portal hypertension. Results: We col…

plateletesophageal band ligation (EBL)clinically significative portal hypertension (CSPH)variceal bleeding (ABV).Medicine (miscellaneous)MELD scorethrombocytopeniaChild–Pugh scorecirrhosi
researchProduct

Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus

2019

Background. Management of venous thromboembolism (VTE) in patients with haematologic malignancies and thrombocytopenia is clinically challenging due to the related risks. No prospective studies or clinical trials have been carried out and, therefore, no solid evidence on this compelling issue is available. Methods. Given this, an expert panel endorsed by the Gruppo Italiano Malattie Ematologiche dell'Adulto Working Party on Thrombosis and Haemostasis was set up to produce a formal consensus, according to the RAND method, in order to issue clinical recommendations about the platelet (PLT) cut-off for safe administration of low molecular weight heparin (LMWH) in thrombocytopenic (PLT <100×…

venous thrombosis thrombocytopenia blood cancer anticoagulant treatment consensusanticoagulantsblood cancerblood plateletsvenous thromboembolismthrombocytopeniaHeparin Low-Molecular-Weightheparinplatelet countanticoagulant treatmentSettore MED/15 - MALATTIE DEL SANGUEVenous thromboembolism haematological malignancythrombocytopeniaconsensuslow-molecular-weightOriginal Articlehematologic neoplasmscardiovascular diseasesvenous thrombosishumansanticoagulant treatment; blood cancer; consensus; thrombocytopenia; venous thrombosis; anticoagulants; blood platelets; heparin low-molecular-weight; humans; platelet count; consensus; hematologic neoplasms; thrombocytopenia; venous thromboembolismAnticoagulant treatment; Blood cancer; Consensus; Thrombocytopenia; Venous thrombosis
researchProduct